Rigel Pharmaceuticals reported $1.32M in Interest Expense on Debt for its third fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Interest Expense On Debt Change
Acura Pharmaceuticals ACUR:US 87K 26K
Alexion Pharmaceuticals ALXN:US $ 27.1M 0.6M
Amgen AMGN:US $ 296M 15M
Applied Genetic Technologies AGTC:US 669K 160K
Biomarin Pharmaceutical BMRN:US $ 3.87M 0.05M
Bristol Myers Squibb BMY:US $ 328M 2M
Chemocentryx CCXI:US $ 0.67M 0.03M
Dicerna Pharmaceuticals DRNA:US $ 0M 0M
Eli Lilly And LLY:US $ 83.6M 3.3M
Flexion Therapeutics FLXN:US $ 6.29M 1.11M
Halozyme Therapeutics HALO:US $ 1.75M 0M
Immunogen IMGN:US $ 2.75M 0.83M
Karyopharm Therapeutics KPTI:US $ 8.01M 3.01M
Ligand Pharmaceuticals LGND:US $ 4.44M 0.44M
Neurocrine Biosciences NBIX:US $ 6.6M 0.4M
Pfizer PFE:US $ 325M 9M
Regeneron Pharmaceuticals REGN:US $ 14.2M 0.2M
Rigel Pharmaceuticals RIGL:US $ 1.32M 0.44M
Veracyte VCYT:US $ 0.06M 0M